Circulating MicroRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes

Diabetes

Volumn 66, Issue 2, 2017, Pages 347-357

  Willeit, Peter ^a,b,c   Skroblin, Philipp ^a   Moschen, Alexander R ^b   Yin, Xiaoke ^a   Kaudewitz, Dorothee ^a   Zampetaki, Anna ^a   Barwari, Temo ^a   Whitehead, Meredith ^a   Ramírez, Cristina M ^d   Goedeke, Leigh ^d   Rotllan, Noemi ^d   Bonora, Enzo ^e   Hughes, Alun D ^f   Santer, Peter ^g   Fernández Hernando, Carlos ^d   Tilg, Herbert ^b   Willeit, Johann ^b   Kiechl, Stefan ^b   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g BRUNECK HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMIN; ALANINE AMINOTRANSFERASE; ANTAGOMIR; APOLIPOPROTEIN; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; COMPLEMENT FACTOR H; GLUCOSE; GLYCOPROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA 122; MONOUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ZINC ALPHA 2 GLYCOPROTEIN; AFM PROTEIN, HUMAN; ANTAGOMIR-122; CARRIER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; MIRN122 MICRORNA, HUMAN; MIRN122 MICRORNA, MOUSE; OLIGONUCLEOTIDE; SERUM ALBUMIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSGLYCEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPIDOMICS; LIVER CELL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOCIAL STATUS; WAIST HIP RATIO; AGED; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; INCIDENCE; MASS SPECTROMETRY; METABOLISM; MULTIVARIATE ANALYSIS; NORTHERN BLOTTING; PREVALENCE; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; ANIMALS; ATORVASTATIN CALCIUM; BLOTTING, NORTHERN; CARRIER PROTEINS; COMPLEMENT FACTOR H; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GLYCOPROTEINS; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEINS, VLDL; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; MICE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OLIGONUCLEOTIDES; PREVALENCE; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM ALBUMIN;

EID: 85011709989     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0731     Document Type: Article

References (45)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233
2. Fernández-Hernando C, Ramírez CM, Goedeke L, Suárez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013;33:178-185
3. Willeit P, Skroblin P, Kiechl S, Fernández-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J 2016;37:3260-3266
4. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98
5. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-689
6. Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899
7. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198-201
8. Gao W, He HW, Wang ZM, et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 2012;11:55
9. Stegemann C, Pechlaner R, Willeit P, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 2014;129:1821-1831
10. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 2014;64:851-860
11. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290-299
12. Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-kB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013;19:358-363
13. Willeit P, Willeit J, Brandstätter A, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2010;30:1649-1656
14. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36:936-942
15. Bonora E, Kiechl S, Willeit J, et al.; Bruneck Study. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003;27:1283-1289
16. Sever PS, Dahlöf B, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-Average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
17. Poulter NR, Wedel H, Dahlöf B, et al.; ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-913
18. Stanton A, Fitzgerald D, Hughes A, et al.; Anglo-Scandinavian Cardiac Outcomes Trial. An intensive phenotyping study to enable the future examination of genetic influences on hypertension-Associated cardiovascular disease. J Hum Hypertens 2001;15(Suppl. 1):S13-S18
19. Zampetaki A, Attia R, Mayr U, et al. Role of miR-195 in aortic aneurysmal disease. Circ Res 2014;115:857-866
20. Werner T, Sweetman G, Savitski MF, Mathieson T, Bantscheff M, Savitski MM. Ion coalescence of neutron encoded TMT 10-plex reporter ions. Anal Chem 2014;86:3594-3601
21. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013;112:595-600
22. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990;9:1501-1515
23. Bertoia ML, Bertrand KA, Sawyer SJ, Rimm EB, Mukamal KJ. Reproducibility of circulating microRNAs in stored plasma samples. PLoS One 2015;10:e0136665
24. Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010;12:19-30; sup pp 1-13
25. Schonewille M, de Boer JF, Mele L, et al. Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. J Lipid Res 2016;57:1455-1464
26. Menon B, Sinden J, Franzo-Romain M, Botta RB, Menon KMJ. Regulation of LH receptor mRNA binding protein by miR-122 in rat ovaries. Endocrinology 2013;154:4826-4834
27. Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012;122:2773-2776
28. Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-2897
29. El Asmar Z, Terrand J, Jenty M, et al. Convergent signaling pathways controlled by LRP1 (receptor-related protein 1) cytoplasmic and extracellular domains limit cellular cholesterol accumulation. J Biol Chem 2016;291:5116-5127
30. Basford JE, Wancata L, Hofmann SM, et al. Hepatic deficiency of low density lipoprotein receptor-related protein-1 reduces high density lipoprotein secretion and plasma levels in mice. J Biol Chem 2011;286:13079-13087
31. Medh JD, Bowen SL, Fry GL, et al. Hepatic triglyceride lipase promotes low density lipoprotein receptor-mediated catabolism of very low density lipoproteins in vitro. J Lipid Res 1999;40:1263-1275
32. Beyoglu D, Krausz KW, Martin J, et al. Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver. J Lipid Res 2014;55:2309-2319
33. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011;121:1402-1411
34. Kronenberg F, Kollerits B, Kiechl S, et al. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet 2014;7:822-829
35. Weismann D, Hartvigsen K, Lauer N, et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011; 478:76-81
36. Garrido-Sánchez L, García-Fuentes E, Fernández-García D, et al. Zinc-Alpha 2-glycoprotein gene expression in adipose tissue is related with insulin resistance and lipolytic genes in morbidly obese patients. PLoS One 2012;7:e33264
37. Yang M, Liu R, Li S, et al. Zinc-A2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 2013;36:1074-1082
38. Würtz P, Wang Q, Kangas AJ, et al. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med 2014;11:e1001765
39. Fall T, Hägg S, Mägi R, et al.; European Network for Genetic and Genomic Epidemiology (ENGAGE) consortium. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med 2013;10:e1001474
40. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol 2011;13:423-433
41. Huang X, Yuan T, Tschannen M, et al. Characterization of human plasmaderived exosomal RNAs by deep sequencing. BMC Genomics 2013;14:319
42. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679
43. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44
44. Jaé N, McEwan DG, Manavski Y, Boon RA, Dimmeler S. Rab7a and Rab27b control secretion of endothelial microRNA through extracellular vesicles. FEBS Lett 2015;589:3182-3188
45. Elgheznawy A, Shi L, Hu J, et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 2015;117:157-165